The short answer
CAS 77591-33-4 is thymosin beta-4's registry number, not TB-500's. TB-500 as the acetylated heptapeptide is PubChem CID 62707662 at 889.0 Da. Material is routinely listed under the parent's CAS, which merges two compounds differing by more than 4 kDa.
Key facts
- CAS 77591-33-4
- Thymosin beta-4 (the parent protein)
- Tβ4 PubChem CID
- 16132341, 4,963 Da
- TB-500 PubChem CID
- 62707662, 889.0 Da
- LKKTETQ CID
- 10169788, 847.0 Da
- Sequence
- Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln
- Practical check
- Mass spectrometry (889 vs 4,963)
Which identifier belongs to which compound
CAS 77591-33-4 resolves to PubChem CID 16132341: C212H350N56O78S, 4,963 Da, forty-three residues. That is thymosin beta-4. TB-500 as the heptapeptide sits at CID 62707662, C38H68N10O14, 889.0 Da. These are separate registrations for separate substances, and quoting the first for the second is not a technicality.
Why the merge happens
TB-500 is a development code rather than a chemical name, so it has no natural identifier of its own in the way a systematic name does. Suppliers and databases reach for the parent protein's CAS because it is the recognised registry entry associated with the name. The practice is understandable and it produces listings where the CAS, the molecular weight and the described sequence do not describe the same molecule.
Research material referenced
TB-500 5mg, third-party HPLC tested
Reading a certificate properly
The sequence is the most informative field. Seven residues, LKKTETQ, means the heptapeptide regardless of what CAS appears at the top. Forty-three residues means full-length thymosin beta-4. If a certificate states a mass near 889 alongside a CAS of 77591-33-4, the document is internally inconsistent and the mass is the field to trust, because it is measured rather than transcribed.
Confirming identity analytically
Mass spectrometry against the theoretical value. There is no ambiguity between 889 and 4,963 on any instrument. The sequence contains no cysteine and no methionine, so the disulfide and +16 Da oxidation satellites common on other peptide spectra should not appear; their presence would indicate something other than the stated compound.
Confirming purity
Reverse-phase HPLC against truncated and deletion sequences. Seven residues is a short synthesis and purity is typically high, so a low figure warrants explanation. Note that full-length thymosin beta-4 at 43 residues is a far harder synthesis with correspondingly more opportunity for deletion sequences, another reason the two products are not interchangeable in practice.
Frequently asked questions
What is TB-500's CAS number?
The heptapeptide has no widely used CAS of its own; it is PubChem CID 62707662. CAS 77591-33-4 belongs to the parent protein, thymosin beta-4.
Is a listing quoting 77591-33-4 wrong?
It is describing thymosin beta-4's registration. Whether it is wrong depends on what is in the vial, which is why the sequence and mass fields matter more.
Which field on a certificate should I trust?
The measured mass and the stated sequence. A CAS number is transcribed; a mass is measured.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubChemPubChem · TB-500 (CID 62707662)pubchem.ncbi.nlm.nih.gov
- PubChemPubChem · Thymosin beta-4 (CID 16132341)pubchem.ncbi.nlm.nih.gov
- PubChemPubChem · LKKTETQ (CID 10169788)pubchem.ncbi.nlm.nih.gov
- PubMedGoldstein AL et al., Thymosin β4: a multi-functional regenerative peptide. Expert Opin Biol Ther 2012 (PMID 22074294)pubmed.ncbi.nlm.nih.gov
- PubMedShrivastava S et al., Thymosin beta4 and cardiac repair. Ann N Y Acad Sci 2010 (PMID 20536454)pubmed.ncbi.nlm.nih.gov
- PubMedSosne G et al., Thymosin beta 4 promotes corneal wound healing. Exp Eye Res 2002 (PMID 11950239)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · Thymosin β4 (RGN-259) dry eye Phase 3 (NCT03925727)clinicaltrials.gov
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More TB-500 (Thymosin β4 fragment) articles
- TB-500 vs Thymosin Beta-4Seven residues against forty-three, 889 Da against 4,963. Which literature applies to which, and why much cited research used the protein, not the fragment.
- Fragment or Full Protein: Which the Research UsesThe heptapeptide isolates the actin-binding motif; the full protein carries everything else. Which to use depends entirely on the question being asked.
- LKKTETQ: The Actin-Binding MotifLKKTETQ occupies residues 17-23 of thymosin beta-4 and carries its actin-binding activity. What the sequence does and why it was isolated.
- How Actin Sequestration WorksThymosin beta-4 binds monomeric G-actin and holds it out of filaments. Why maintaining a monomer pool matters for how quickly a cell can rebuild its skeleton.
- How Thymosin Beta-4 Was DiscoveredLow and colleagues published the complete sequence of bovine thymosin beta-4 in PNAS in February 1981, describing it as a thymic hormone. That framing changed.